Product
VG2025
Name
VG2025
2 clinical trials
1 drug
3 indications
Indication
Solid TumorIndication
Advanced Solid TumorIndication
CarcinomatosisDrug
VG2025Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With CarcinomatosisStatus: Not yet recruiting, Estimated PCD: 2028-03-22